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background: Direct current cardioversion (DCCV) for persistent atrial fibrillation/atrial flutter (AF) carries a risk of thromboembolic events (TE). 
Therapeutic anticoagulation with warfarin is recommended for 3-4 weeks before and 4 weeks after DCCV to reduce TE; however the safety of short-
term anticoagulation with the novel oral anticoagulants (Dabigatran, Rivaroxaban, Apixiban) (NOAC) prior to DCCV has not been assessed.
methods: A retrospective cohort study was performed on all patients undergoing elective DCCV for AF at Northwestern Memorial Hospital from 
6/1/2012 to 9/30/2013. Inclusion criteria included patients on any of the NOACs for 21-60 days prior to DCCV and successful DCCV to sinus 
rhythm. Patients were followed up for 60 days post DCCV to evaluate for TE including stroke, transient ischemic attack, and death.
results: In total 53 patients (46 male, 86.8%) (Age 64.6 +/- 10.2 years) were evaluated. Agents used were Dabigatran (29, 54.7%), Rivaroxaban 
(23, 43.4%), Apixiban (1, 1.9%) for an average of 38.2 +/- 9.3 days. Prevalence of stroke risk factors included congestive heart failure 15.1%, 
hypertension 58.5%, age ≥ 75 years 15.1%, diabetes mellitus 17.0%, previous stroke or transient ischemic attack 5.7%. The mean CHADS2 score 
was 1.2 +/- 1.0 (Score = 0, 26.4%; 1, 43.4%; 2, 18.9%; > 3, 11.3%). Eleven patients (20.7%) had a trans-esophageal echocardiogram (TEE) prior to 
their DCCV; all showed no thrombus. No patients were found to have episodes of TE within 60 days of DCCV.
conclusion: The use of short-term NOAC therapy for DCCV of AF appears safe; larger studies are necessary to confirm these findings.
